The Spectranetics Corp (NASDAQ:SPNC)

CAPS Rating: 2 out of 5

The Company develops, manufactures, markets and distributes single-use medical devices used in minimally invasive surgical procedures within the cardiovascular system in conjunction with its proprietary excimer laser system.

Results 1 - 20 of 20

Recs

0
Member Avatar TSIF (99.96) Submitted: 4/8/2014 5:50:35 PM : Outperform Start Price: $23.00 SPNC Score: +1.14

Short term trade....not a good one....

Dropped 12% and more than filled the gap after guiding lower.
Revenue growing 3-5%, margins 72%.
Blamed on disruption to sales team...(poor management?)
Expects 7.5-9M net loss for full 2014. Well within cash flow, no issues there.
BUT companies that are going from negative to positive typically receive huge accolades from the market.
Saying you are staying negative for a full year, sniffs of dead money....investors dont' like that....

Short term call....if it goes back green....

Recs

0
Member Avatar OklaBoston (68.62) Submitted: 4/7/2014 4:23:18 PM : Underperform Start Price: $22.57 SPNC Score: -2.93

Bad Q/Q and ugly valuations.

Recs

0
Member Avatar followerofBasho (73.36) Submitted: 10/17/2011 9:37:45 PM : Outperform Start Price: $7.02 SPNC Score: +177.59

The strong inventory trend matched with the rising price caught my eye, Good feeling about this one.

Recs

0
Member Avatar anchor68 (74.47) Submitted: 8/30/2011 11:45:37 PM : Outperform Start Price: $6.25 SPNC Score: +221.26

Undervalued at $6.23! They will beat their year high of $7.21 very soon. Their technology makes minimally invasive procedures easier for cardiologists & other specialists. The baby boomer population is growing older, so they'll be plenty of new patients. I'm Long on SPNC!

Recs

0
Member Avatar Lfierz (53.13) Submitted: 3/5/2010 12:38:47 PM : Outperform Start Price: $7.45 SPNC Score: +149.99

because of growing business

Recs

0
Member Avatar yes2jbs (94.60) Submitted: 2/27/2010 11:05:39 AM : Underperform Start Price: $6.68 SPNC Score: -182.11

Good company, but is overextended on price. Too bad we are in a bear market...

Recs

0
Member Avatar zamboni56 (46.43) Submitted: 5/29/2008 12:51:34 PM : Outperform Start Price: $11.19 SPNC Score: +71.79

innovative product, moat of protection, great growth potential

Recs

0
Member Avatar SportAg22 (< 20) Submitted: 4/17/2008 12:57:54 PM : Outperform Start Price: $8.51 SPNC Score: +132.62

The margin on single-use medical devices is incredibly high! The demand for surgery will be increasing over time as well... also insurance companies reimburse for minimally invasive procedures because the risk for complications is lower.

Recs

0
Member Avatar metalgearhmn (75.42) Submitted: 2/21/2008 6:41:45 PM : Outperform Start Price: $8.80 SPNC Score: +121.74

Dropped too much too quickly, short term rebound is expected. Also no debt, and liabilites are ok given revenue? Not really sure about long term prospects, but again, it should rebound.

Recs

0
Member Avatar Abukashif (< 20) Submitted: 10/19/2007 8:34:17 PM : Outperform Start Price: $15.06 SPNC Score: +24.61

Minimally invasive surgery has a bright future and SPNC is the best of the group.

Recs

0
Member Avatar stockscreener (56.29) Submitted: 8/9/2007 11:35:27 AM : Outperform Start Price: $15.09 SPNC Score: +22.86

FDA approval on an exclusive product.

Recs

0
Member Avatar ProphetOfProfits (38.30) Submitted: 7/13/2007 6:07:41 AM : Outperform Start Price: $12.02 SPNC Score: +65.30

As long as the 7/23 earning report is OK, everything looks rosy given the recent FDA approval of the Turbo Baster and until yesterday, catheter use was limited to total occlusions that cannot be crossed with theguide wire. Following the FDA announcement - these restrictions are now gone. This means that physicians can now go to the laser for any blockage in the leg they want to and the mkt potential increases 3-5x.

This is a buyout candidate in the low 20's range.

Recs

0
Member Avatar edinberlin (71.32) Submitted: 3/15/2007 9:21:22 AM : Outperform Start Price: $10.72 SPNC Score: +76.01

None

Recs

1
Member Avatar NetscribeHealthC (25.85) Submitted: 2/9/2007 7:44:00 AM : Outperform Start Price: $10.70 SPNC Score: +82.32

Spectranetics (SPNC) develops, manufactures, markets and distributes medical devices used in minimally invasive procedures within the cardiovascular system in conjunction with its Excimer Laser Ablation (ELA) system. The ELA system includes the CVX-300 laser unit and various fiber-optic delivery devices like disposable catheters and sheaths. The CVX-300 is the only ELA system approved by the US FDA for the treatment of multiple cardiovascular diseases. Its worldwide installed capacity currently totals nearly 550 laser systems, 87% of which are in the United States. The company also offers its products in Canada, Mexico, South America, the Pacific Rim, and Australia.

The Peripheral Artery Disease (PAD) affects 8 to 12 million Americans every year, of whom only about 25% are diagnosed as suffering from the same. Driven by an increasing prevalence of PAD among the aging US population, a growing awareness of the disease and its diagnosis and the rapid introduction of innovative diagnostic technologies, the market is expected to increase at an annual rate of approximately 18% over the next five years. Spectranetics is well positioned to capitalize on this growth in the coming years as it has an established technology platform, growing sales force and an expanding base of physicians.

The company has posted sequential revenue growth in each of its past seven quarters. For the nine months ended 30 September 2006, its revenues increased 48% reflecting an increase of 52% and 45% in disposable products and laser revenue respectively. In third quarter of 2006, the company also announced regulatory approval for the TURBO Booster. However, the company expects a limited release of the product by 2006 end, with a full market launch in early 2007.

A strong market position, technological advancement, new product launch and a capable management would enable the company’s sales to rise by atleast 30% during 2007 making the company a likely outperformer.

Recs

0
Member Avatar docracer (< 20) Submitted: 2/8/2007 10:56:07 PM : Outperform Start Price: $10.70 SPNC Score: +82.32

unique products,growing marketing and sales forces will lead to sales growth and market share. They may be a prime candidate for a take-over by a larger player like Boston Scientific.

Recs

0
Member Avatar 5STARsmallCAPS (68.47) Submitted: 11/11/2006 9:11:26 PM : Outperform Start Price: $11.49 SPNC Score: +60.68

5-star $363 million market cap on 11/11/06
Angioplasty devices.
5STARsmallCAPS picks five star stocks with the smallest market caps.

Recs

0
Member Avatar macmcmeg (< 20) Submitted: 10/28/2006 11:43:52 AM : Outperform Start Price: $13.34 SPNC Score: +32.06

Huge growth in an underserved medical market for an aging population.

Recs

0
Member Avatar Christocruix (< 20) Submitted: 10/18/2006 11:43:23 PM : Outperform Start Price: $13.11 SPNC Score: +33.80

Obesity is a heart attack waiting. It seems a good idea to focus on this market as people get older, they will need it more.

Recs

1
Member Avatar cancermango (64.35) Submitted: 10/18/2006 7:14:35 PM : Outperform Start Price: $13.00 SPNC Score: +35.47

One thing people will never do is eat healthy. The "I need to vaporize the clots in my arteries and veins" market is only going to continue to grow, and Spectranetics has a product that has a lot of potential in this field. Right now it's being used mostly to treat PAD, but I believe if it can be proven as safe in the treatment of ailments with larger markets, the potential for this small little company to go big time is there. Until then, they've only got 4% of the PAD market, so they've got a lot of growth opportunity already. The Clirpath excimer laser was on Medical Marvels on the History Channel(or one of those shows), getting the word out is 99% of the battle.

Recs

2
Member Avatar TMFBreakerJava (99.50) Submitted: 7/27/2006 12:25:38 PM : Outperform Start Price: $12.00 SPNC Score: +39.43

This intravascular laser company seems to be gaining traction. Expect to outperform the market from here.

Results 1 - 20 of 20

Featured Broker Partners


Advertisement